The Misuse of Drugs Regulations 2001

Regulation 3

SCHEDULE 1CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27

1.  The following substances and products, namely -

(a)Bufotenine

• Cannabinol

• Cannabinol derivatives not being dronabinol or its stereoisomers

• Cannabis and cannabis resin

• Cathinone

• Coca leaf

• Concentrate of poppy-straw

• Eticyclidine

• Etryptamine

• Lysergamide

• Lysergide and other N-alkyl derivatives of lysergamide

• Mescaline

• Methcathinone

• Psilocin

• Raw opium

• Rolicyclidine

• Tenocyclidine

• 4-Bromo-2,5-dimethoxy-a-methylphenethylamine

• N,N-Diethyltryptamine

• N,N-Dimethyltryptamine

• 2,5-Dimethoxy-α,4-dimethylphenethylamine

• N-Hydroxy-tenamphetamine

• 4-Methyl-aminorex

(b)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c)the following phenethylamine derivatives, namely—

• Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine

• 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

• 2-Amino-1-(3,4-dimethoxyphenyl)ethanol

• Benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine

• 4-Bromo-β,2,5-trimethoxyphenethylamine

• N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

• Cyclopropylmethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

• 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

• 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

• 2-(1,4-Dimethoxy-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

• N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

• 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

• α, α-Dimethyl-3,4-methylenedioxyphenethylamine

• α,α-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

• Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

• N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

• 4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

• 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

• 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• 2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

• 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

• β-Methoxy-3,4-methylenedioxyphenethylamine

• 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

• 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

• 2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol

• α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

• N-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

• α-Methyl-4-(methylthio)phenethylamine

• β,3,4,5-Tetramethoxyphenethylamine

• β,2,5-Trimethoxy-4-methylphenethylamine

(d)any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, α-methylphenethylamine, an N-alkyl-α-methylphenethylamine, α-ethylphenethylamine, or an N-alkyl-α-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;

(e)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -

(i)by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii)by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii)by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv)by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v)by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi)by replacement of the N-propionyl group by another acyl group;

(f)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—

(i)by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii)by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii)by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv)by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v)by formation of an N-oxide or of a quaternary base.

2.  Any stereoisomeric form of a substance specified in paragraph 1.

3.  Any ester or ether of a substance specified in paragraph 1 or 2.

4.  Any salt of a substance specified in any of paragraphs 1 to 3.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.

Regulation 3

SCHEDULE 2CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 21, 23, 26 AND 27

1.  The following substances and products, namely—

2.  Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.

3.  Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.

4.  Any salt of a substance specified in any of paragraphs 1 to 3.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.

6.  The following substances and products, namely—

7.  Any stereoisomeric form of a substance specified in paragraph 6.

8.  Any salt of a substance specified in paragraph 6 or 7.

9.  Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.

Regulation 3

SCHEDULE 3CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15 (EXCEPT TEMAZEPAM), 16, 18, 22, 23, 24, 26 AND 27

1.  The following substances, namely—

(b)any 5, 5 disubstituted barbituric acid not being quinalbarbitone.

2.  Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine.

3.  Any salt of a substance specified in paragraph 1 or 2.

4.  Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

Regulation 3

SCHEDULE 4

PART ICONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances and products, namely—

2.  Any stereoisomeric form of a substance specified in paragraph 1.

3.  Any salt of a substance specified in paragraph 1 or 2.

4.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

PART IICONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON POSSESSION WHEN IN THE FORM OF A MEDICINAL PRODUCT; EXCLUDED FROM THE APPLICATION OF OFFENCES ARISING FROM THE PROHIBITION ON IMPORTATION AND EXPORTATION WHEN IMPORTED OR EXPORTED IN THE FORM OF A MEDICINAL PRODUCT BY ANY PERSON FOR ADMINISTRATION TO HIMSELF; AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances, namely—

2.  Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -

(a)by further substitution at position 17 by a methyl or ethyl group;

(b)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(c)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(d)by fusion of ring A with a heterocyclic system.

3.  Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.

4.  The following substances, namely—

• Chorionic Gonadotrophin (HCG)

• Clenbuterol

• Non-human chorionic gonadotrophin

• Somatotropin

• Somatrem

• Somatropin

5.  Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.

6.  Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.

7.  Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.

Regulation 3

SCHEDULE 5CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON IMPORTATION, EXPORTATION AND POSSESSION AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 24 AND 26

1.—(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.

(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.

2.  Any preparation of cocaine containing not more than 0.1% of cocaine calculated as cocaine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the cocaine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.

3.  Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.

4.  Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.

5.  Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin.

6.  Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.

7.  Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.

8.  Any powder of ipecacuanha and opium comprising—

• 10% opium, in powder,

• 10% ipecacuanha root, in powder, well mixed with

• 80% of any other powdered ingredient containing no controlled drug.

9.  Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.

Regulation 19

SCHEDULE 6FORM OF REGISTER

PART IEntries to be made in case of obtaining

PART IIEntries to be made in case of supply

Regulation 28

SCHEDULE 7REGULATIONS REVOKED